rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2017-4-1-6rpmj-172Research ArticleОбзорыReviewТИМИДИНКИНАЗА-I (ТК-1) КАК ПОТЕНЦИАЛЬНЫЙ ОПУХОЛЕАССОЦИИРОВАННЫЙ МАРКЕР: СЫВОРОТОЧНЫЕ УРОВНИ У БОЛЬНЫХ С СОЛИДНЫМИ И СИСТЕМНЫМИ ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИTHE THYMIDINE KINASE-1(TK-1) AS A POTENTIAL TUMOR MARKER: SERUM LEVELS IN SERUM OF PATIENTS WITH SOLID AND SYSTEM MALIGNANCE NEOPLASMSСергееваН. С.SergeevaN. S.

д. б.н., руководитель отделения прогноза эффективности консервативного лечения, 125284, Москва, 2-й Боткинский проезд, 3;

профессор кафедры биологии, 117997, Москва, ул. Островитянова, 1

MD, Head of the Department of Forecast of the Effectiveness of Conservative Treatment, 3, 2nd Botkinsky proezd, Moscow 125284;

Professor of the Department of Biology, 1 ul. Ostrovityanova, Moscow 117997

ПариловаН. К.ParilovaN. K.

младший научный сотрудник отделения прогноза эффективности консервативного лечения,

125284, Москва, 2-й Боткинский проезд, 3

junior researcher, Department of Forecast of the Effectiveness of Conservative Treatment,

3, 2nd Botkinsky proezd, Moscow 125284

prognoz.06@mail.ruМаршутинаН. В.MarshutinaN. V.

к. б.н., старший научный сотрудник отделения прогноза эффективности консервативного лечения,

125284, Москва, 2-й Боткинский проезд, 3

PhD, senior researcher, Department of Forecast of the Effectiveness of Conservative Treatment,

3, 2nd Botkinsky proezd, Moscow 125284

ТюринаН. Г.TyurinaN. G.

к.м.н., руководитель отделения высокодозной химиотерапии,

125284, Москва, 2-й Боткинский проезд, 3

PhD, Head of High-dose Chemotherapy Department, 

3, 2nd Botkinsky proezd, Moscow 125284

МустафинА. Г.MustafinA. G.

д.м.н., заведующий кафедрой биологии,

117997, Москва, ул. Островитянова, 1

MD, Head of the Department of Biology,

1 ul. Ostrovityanova, Moscow 117997

Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России; ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University, the Ministry of Health of the Russian FederationRussian FederationМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииРоссияP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical University, the Ministry of Health of the Russian FederationRussian Federation201723032017414957Copyright © Сергеева Н.С., Парилова Н.К., Маршутина Н.В., Тюрина Н.Г., Мустафин А.Г., 20172017Сергеева Н.С., Парилова Н.К., Маршутина Н.В., Тюрина Н.Г., Мустафин А.Г.Sergeeva N.S., Parilova N.K., Marshutina N.V., Tyurina N.G., Mustafin A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/172

В обзоре обобщены результаты исследований уровней и/или активности в сыворотке крови метаболического маркера пролиферирующих клеток тимидинкиназы-1 (ТК-1) у больных лимфопролиферативными заболеваниями (ЛПЗ) и солидными злокачественными новообразованиями (ЗНО).

Сопоставление данных литературы в ряде случаев было затруднено из-за использования авторами принципиально разных методов выявления активности или концентрации ТК-1, даже несмотря на наличие относительно высокой (но не абсолютной) корреляции между этими показателями (не более 0,8).

Многие клинико-лабораторные исследования свидетельствуют о корреляции уровней и/или активности ТК-1 с клиническими стадиями разных видов ЛПЗ и солидных ЗНО и могут служить прогностическим фактором общей и безрецидивной выживаемости больных. При солидных ЗНО показано, что активность ТК-1 адекватно отражает пролиферативный статус опухолей.

При сопоставлении динамики ТК-1 в процессе химиотерапии с ее клинической эффективностью разные авторы получили принципиально различающиеся результаты: в ряде случаев снижение маркера было ассоциировано с эффективностью лечения, а в части публикаций показано, что при клинически значимых эффектах лечения наблюдается повышение маркера после первых курсов химиотерапии.

Вся совокупность полученных к настоящему времени данных свидетельствует об актуальности дальнейших разработок алгоритма использования ТК-1 в онкологической практике.

The review summarizes the results of studies of levels and/or activity in the blood serum of a metabolic marker thymidine kinase-1 (TK-1) of proliferating cells in patients with lymphoproliferative diseases (LPD) and malignant neopasms (NM).

Comparison of the data in the literature in some cases have been difficult due to the fundamentally different methods of detection the activity or concentration of TK-1, used by authors, even despite the presence of relatively high (but not absolute) correlation between these parameters (maximum 0.8).

Many clinical and laboratory studies have shown levels of correlation and/or TK-1 activity with clinical stages and different types of LPD and solid MN and can serve as a prognostic factor for overall and recurrence-free survival of patients. When solid MN shown that the activity of TK-1 accurately reflects the proliferative status of tumor.

A comparison of the dynamics of TC-1 in the process of chemotherapy and its clinical efficacy, different authors have received fundamentally different results: in some cases the marker reduction was associated with treatment efficacy, and in part of publications they show that the clinically relevant effects of the treatment observed increase in the marker after the first chemotherapy.

The entire set of received data demonstrates the relevance of the further development of the algorithm use of TK-1 in oncology practice.

тимидинкиназа-1 (ТК-1)лимфопролиферативные заболевания (ЛПЗ)солидные злокачественные новообразованияопухолеассоциированный маркерthymidine kinase-1 (TK-1)lymphoproliferative disease (LPD)solid malignanciestumor-associated markerReferencesСергеева Н.С., Парилова Н. К., Маршутина Н.В., Мейснер И.С. Тимидинкиназа-I (ТК-1) как потенциальный опухолеассоциированный маркер: структура, функции, активность в нормальных и опухолевых тканях. Успехи молекулярной онкологии. 2017. (принят к печати)./Sergeeva NS, Parilova NK, Marshutina NV, Meisner IS. Timidinkinaza-I (TK-1) kak potentsial’nyi opukholeassotsiirovannyi marker: struktura, funktsii, aktivnost’ v normal’nykh i opukholevykh tkanyakh. Advances in Molecular Oncology. 2017. In Print. (In Russian).Сергеева Н.С., Парилова Н. К., Маршутина Н.В., Мейснер И.С. Тимидинкиназа-I (ТК-1) как потенциальный опухолеассоциированный маркер: структура, функции, активность в нормальных и опухолевых тканях. Успехи молекулярной онкологии. 2017. (принят к печати)./Sergeeva NS, Parilova NK, Marshutina NV, Meisner IS. Timidinkinaza-I (TK-1) kak potentsial’nyi opukholeassotsiirovannyi marker: struktura, funktsii, aktivnost’ v normal’nykh i opukholevykh tkanyakh. Advances in Molecular Oncology. 2017. In Print. (In Russian).Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988 Jun 15; 263 (17): 8350–8358. Available at: http://www.jbc.org/content/263/17/8350.longSherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988 Jun 15; 263 (17): 8350–8358. Available at: http://www.jbc.org/content/263/17/8350.longGasparri F, Wang N, Skog S, Galvani A, Eriksson S. Thymidine kinase 1 expression defines as activated G1 state of cell cycle as revealed with site-specific antibodies and ArrayScanTM assays. Eur J Cell Biol. 2009 Dec; 88 (12): 779–85. DOI: 10.1016/j.ejcb.2009.06.005Gasparri F, Wang N, Skog S, Galvani A, Eriksson S. Thymidine kinase 1 expression defines as activated G1 state of cell cycle as revealed with site-specific antibodies and ArrayScanTM assays. Eur J Cell Biol. 2009 Dec; 88 (12): 779–85. DOI: 10.1016/j.ejcb.2009.06.005Coppock DL, Pardee AB. Control of thymidine kinase mRNA during the cell cycle. Mol Cell Biol. 1987; 7 (8): 2925–2932. DOI: 10.1128/MCB.7.8.2925Coppock DL, Pardee AB. Control of thymidine kinase mRNA during the cell cycle. Mol Cell Biol. 1987; 7 (8): 2925–2932. DOI: 10.1128/MCB.7.8.2925Gross MK, Kainz MS, Merrill GF. The chicken thymidine kinase gene is transcriptionally repressed during terminal differentiation: the associated decline in TK mRNA cannot account fully for the disappearance of TK enzyme activity. Dev Biol. 1987; 122 (2): 439–451. DOI: 10.1016/0012–1606 (87)90308–3Gross MK, Kainz MS, Merrill GF. The chicken thymidine kinase gene is transcriptionally repressed during terminal differentiation: the associated decline in TK mRNA cannot account fully for the disappearance of TK enzyme activity. Dev Biol. 1987; 122 (2): 439–451. DOI: 10.1016/0012–1606 (87)90308–3Gronowitz JS, Hagberg H, Källander CF, Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin’s lymphoma. Br J Cancer. 1983 Apr; 47 (4): 487–495. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011337/Gronowitz JS, Hagberg H, Källander CF, Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin’s lymphoma. Br J Cancer. 1983 Apr; 47 (4): 487–495. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011337/Sampi K, Takagi T, Sakai C, Kuraishi Y, Ishige K. Clinical application of thymidine kinase activity in patients with acute non-lymphocytic leukemia. Gan To Kagaku Ryoho. 1991 Jan; 18 (1): 69–73.Sampi K, Takagi T, Sakai C, Kuraishi Y, Ishige K. Clinical application of thymidine kinase activity in patients with acute non-lymphocytic leukemia. Gan To Kagaku Ryoho. 1991 Jan; 18 (1): 69–73.Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul; 65 (1): 1–5.Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul; 65 (1): 1–5.Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999 Mar 1; 93 (5): 1732–1737. Available at: http://www.bloodjournal.org/content/93/5/1732.long?sso-checked=trueHallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999 Mar 1; 93 (5): 1732–1737. Available at: http://www.bloodjournal.org/content/93/5/1732.long?sso-checked=trueAul C, Gattermann N, Germing U, Winkelmann M, Heyll A, Runde V, et al. Serum deoxythymidine kinase in myelodysplastic syndromes. Cancer. 1994 Jan 15; 73 (2): 322–327.Aul C, Gattermann N, Germing U, Winkelmann M, Heyll A, Runde V, et al. Serum deoxythymidine kinase in myelodysplastic syndromes. Cancer. 1994 Jan 15; 73 (2): 322–327.Welin M, Kosinska U, Mikkelsen N-E, Carnrot C, Zhu C, Wang L, et al. Structures of thymidine kinase 1 of human and mycoplasma origin. Proc Natl Acad Sci USA. 2004; 102: 17970–17975. DOI: 10.1073/pnas.0406332102Welin M, Kosinska U, Mikkelsen N-E, Carnrot C, Zhu C, Wang L, et al. Structures of thymidine kinase 1 of human and mycoplasma origin. Proc Natl Acad Sci USA. 2004; 102: 17970–17975. DOI: 10.1073/pnas.0406332102Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013 Jan; 1 (1): 18–28. DOI: 10.3892/mco.2012.19Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013 Jan; 1 (1): 18–28. DOI: 10.3892/mco.2012.19Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods. 2003 Jun 1; 277 (1–2): 157–169. DOI: 10.1016/S0022–1759 (03)00062–0Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods. 2003 Jun 1; 277 (1–2): 157–169. DOI: 10.1016/S0022–1759 (03)00062–0Kuroiwa N, Nakayama M, Fukuda T, Fukui H, Ohwada H, Hiwasa T, et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J Immunol Methods. 2001 Jul 1; 253 (1–2): 1–1. DOI: 10.1016/S0022–1759 (01)00368–4Kuroiwa N, Nakayama M, Fukuda T, Fukui H, Ohwada H, Hiwasa T, et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J Immunol Methods. 2001 Jul 1; 253 (1–2): 1–1. DOI: 10.1016/S0022–1759 (01)00368–4Ohrvik A, Lindh M, Einarsson R, Grassi J, Eriksson S. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin Chem. 2004 Sep; 50 (9): 1597–1606. DOI: 10.1373/clinchem.2003.030379Ohrvik A, Lindh M, Einarsson R, Grassi J, Eriksson S. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin Chem. 2004 Sep; 50 (9): 1597–1606. DOI: 10.1373/clinchem.2003.030379Zhang F, Li H, Pendleton AR, Robison JG, Monson KO, Murray BK, et al. Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev. 2001; 25 (1): 8–15.Zhang F, Li H, Pendleton AR, Robison JG, Monson KO, Murray BK, et al. Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev. 2001; 25 (1): 8–15.Zou L, Zhang PG, Zou S, Li Y, He Q. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers. 2002 Apr-Jun; 17 (2): 135–140.Zou L, Zhang PG, Zou S, Li Y, He Q. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers. 2002 Apr-Jun; 17 (2): 135–140.He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006 Nov-Dec; 26 (6C): 4753–4759. Available at: http://ar.iiarjournals.org/content/26/6C/4753.longHe Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2006 Nov-Dec; 26 (6C): 4753–4759. Available at: http://ar.iiarjournals.org/content/26/6C/4753.longXu W, Shen QD, Yu H, Qiao C, Wu YJ, Liu Q, et al. Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors. Zhonghua Xue Ye Xue Za Zhi. 2009 Jan; 30 (1): 8–12.Xu W, Shen QD, Yu H, Qiao C, Wu YJ, Liu Q, et al. Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors. Zhonghua Xue Ye Xue Za Zhi. 2009 Jan; 30 (1): 8–12.Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu Q, et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol. 2009 Sep; 90 (2): 205–11. DOI: 10.1007/s12185–009–0380–8Xu W, Cao X, Miao KR, Qiao C, Wu YJ, Liu Q, et al. Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. Int J Hematol. 2009 Sep; 90 (2): 205–11. DOI: 10.1007/s12185–009–0380–8Konoplev SN, Fritsche HA, O’Brien S, Wierda WG, Keating MJ, Gornet TG, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010 Sep; 134 (3): 472–477. DOI: 10.1309/AJCPHMYT93HUIZKWKonoplev SN, Fritsche HA, O’Brien S, Wierda WG, Keating MJ, Gornet TG, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010 Sep; 134 (3): 472–477. DOI: 10.1309/AJCPHMYT93HUIZKWMagnac C, Porcher R, Davi F, Nataf J, Payelle-Brogard B, Tang RP, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003 Jan; 17 (1): 133–137. DOI: 10.1038/sj.leu.2402780Magnac C, Porcher R, Davi F, Nataf J, Payelle-Brogard B, Tang RP, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003 Jan; 17 (1): 133–137. DOI: 10.1038/sj.leu.2402780Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O’Brien S, Kantarjian H, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Annals of Oncology. 2001; 12 (5): 621–625.Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O’Brien S, Kantarjian H, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Annals of Oncology. 2001; 12 (5): 621–625.Fan L, Wang L, Zhang R, Fang C, Zhu DX, Wang YH, et al. Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Sep; 53 (9): 1749–1756. DOI: 10.3109/10428194.2012.664845Fan L, Wang L, Zhang R, Fang C, Zhu DX, Wang YH, et al. Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Sep; 53 (9): 1749–1756. DOI: 10.3109/10428194.2012.664845Загоскина Т.П., Зотина Е.Н., Крюкова М. Г., Куликова М.М., Шардаков В.И. Содержание тимидинкиназы в сыворотке крови у больных хроническим лимфолейкозом. Практическая медицина. 2012; 5 (60): 138–142./Zagoskina TP, Zotina EN, Kryukova MG, Kulikova MM, Shardakov VI. Serum thymidine kinase content in patients with chronic lymphocytic leukemia. Practical Medicine. 2012; 5 (60): 138–142. (In Russian).Загоскина Т.П., Зотина Е.Н., Крюкова М. Г., Куликова М.М., Шардаков В.И. Содержание тимидинкиназы в сыворотке крови у больных хроническим лимфолейкозом. Практическая медицина. 2012; 5 (60): 138–142./Zagoskina TP, Zotina EN, Kryukova MG, Kulikova MM, Shardakov VI. Serum thymidine kinase content in patients with chronic lymphocytic leukemia. Practical Medicine. 2012; 5 (60): 138–142. (In Russian).Загоскина Т.П., Зотина Е.Н., Крюкова М. Г., Шардаков В.И., Гришина И.В. Значение сывороточной тимидинкиназы в прогрессировании ответа на терапию у больных хроническим лимфолейкозом. Сибирский научный медицинский журнал. 2013; 33 (1): 10–14./Zagoskina TP, Zotina EN, Kryukova MG, Shardakov VI, Grishina IV. Significance of serum thymidine kinase in prediction of the response to therapy in patients with chronic lymphocytic leukemia. The Siberian Scientific Medical Journal. 2013; 33 (1): 10–14. (In Russian).Загоскина Т.П., Зотина Е.Н., Крюкова М. Г., Шардаков В.И., Гришина И.В. Значение сывороточной тимидинкиназы в прогрессировании ответа на терапию у больных хроническим лимфолейкозом. Сибирский научный медицинский журнал. 2013; 33 (1): 10–14./Zagoskina TP, Zotina EN, Kryukova MG, Shardakov VI, Grishina IV. Significance of serum thymidine kinase in prediction of the response to therapy in patients with chronic lymphocytic leukemia. The Siberian Scientific Medical Journal. 2013; 33 (1): 10–14. (In Russian).Hagag AA, Saad MA, Mohamed SA. Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia. South Asian J Cancer. 2015 AprJun; 4 (2): 72–74. DOI: 10.4103/2278–330X.155675Hagag AA, Saad MA, Mohamed SA. Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia. South Asian J Cancer. 2015 AprJun; 4 (2): 72–74. DOI: 10.4103/2278–330X.155675Wang TJ, Sun AN, Wu DP, Li WY, Liang JY. Analysis of correlation between serum thymidine kinase 1 and acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct; 21 (5): 1095–1098. DOI: 10.7534/j.issn.1009–2137.2013.05.002Wang TJ, Sun AN, Wu DP, Li WY, Liang JY. Analysis of correlation between serum thymidine kinase 1 and acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct; 21 (5): 1095–1098. DOI: 10.7534/j.issn.1009–2137.2013.05.002O’Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1 — A prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007; 21: 560–563. DOI: 10.1038/sj.leu.2404536O’Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1 — A prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007; 21: 560–563. DOI: 10.1038/sj.leu.2404536Zhang F, Shao X, Li H, Robison JG, Murray BK, O’Neill KL. A monoclonal antibody specific for human thymidine kinase 1. Hybridoma. 2001; 20 (1): 25–34. DOI: 10.1089/027245701300060382Zhang F, Shao X, Li H, Robison JG, Murray BK, O’Neill KL. A monoclonal antibody specific for human thymidine kinase 1. Hybridoma. 2001; 20 (1): 25–34. DOI: 10.1089/027245701300060382Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010 Aug; 136 (8): 1193–1199. DOI: 10.1007/s00432–010–0769-zPan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010 Aug; 136 (8): 1193–1199. DOI: 10.1007/s00432–010–0769-zHe E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma. Nucleosides Nucleotides Nucleic Acids. 2010 Jun; 29 (4–6): 352–358. DOI: 10.1080/15257771003738535He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin’s lymphoma. Nucleosides Nucleotides Nucleic Acids. 2010 Jun; 29 (4–6): 352–358. DOI: 10.1080/15257771003738535Горяинова Н.В., Третьяк Н.М., Миронова О.В. Взаимосвязь между уровнем тимидинкиназы в сыворотке крови больных на острую миелобластную лейкемию и рецидивом заболевания. Украинский онкологический журнал. 2006; 4 (14): 427./Goryainova NV, Tret’yak NM, Mironova OV. Vzaimosvyaz’ mezhdu urovnem timidinkinazy v syvorotke krovi bol’nykh na ostruyu mieloblastnuyu leikemiyu i retsidivom zabolevaniya. Ukrainskii onkologicheskii zhurnal. 2006; 4 (14): 427. (In Russian).Горяинова Н.В., Третьяк Н.М., Миронова О.В. Взаимосвязь между уровнем тимидинкиназы в сыворотке крови больных на острую миелобластную лейкемию и рецидивом заболевания. Украинский онкологический журнал. 2006; 4 (14): 427./Goryainova NV, Tret’yak NM, Mironova OV. Vzaimosvyaz’ mezhdu urovnem timidinkinazy v syvorotke krovi bol’nykh na ostruyu mieloblastnuyu leikemiyu i retsidivom zabolevaniya. Ukrainskii onkologicheskii zhurnal. 2006; 4 (14): 427. (In Russian).Мазур А. Г., Миронова А.В., Ткаченко М.Н., Горяинова Н.В. Сравнительное исследование опухолевых маркеров тимидинкиназы и β2-микроглобулина у больных острой миелобластной лейкемией как прогностических факторов. Украинский радиологический журнал. 2012; 3 (20): 314–318./Mazur AG, Mironova AV, Tkachenko MN, Goryainova NV. Sravnitel’noe issledovanie opukholevykh markerov timidinkinazy i β2-mikroglobulina u bol’nykh ostroi mieloblastnoi leikemiei kak prognosticheskikh faktorov. Ukrainskii radiologicheskii zhurnal. 2012; 3 (20): 314–318. (In Russian).Мазур А. Г., Миронова А.В., Ткаченко М.Н., Горяинова Н.В. Сравнительное исследование опухолевых маркеров тимидинкиназы и β2-микроглобулина у больных острой миелобластной лейкемией как прогностических факторов. Украинский радиологический журнал. 2012; 3 (20): 314–318./Mazur AG, Mironova AV, Tkachenko MN, Goryainova NV. Sravnitel’noe issledovanie opukholevykh markerov timidinkinazy i β2-mikroglobulina u bol’nykh ostroi mieloblastnoi leikemiei kak prognosticheskikh faktorov. Ukrainskii radiologicheskii zhurnal. 2012; 3 (20): 314–318. (In Russian).López-Martínez B, Ordoñez AV, Garcia MS, Klünder MK, Parra-Ortega I, Acosta ED, et al. Thymidine Kinase: A Biomarker for Recently Diagnosed Acute Leukemia in Pediatric Patients According to the Cell Line Involved. Arch Med Res. 2015 Nov 30. DOI: 10.1016/j.arcmed.2015.11.005López-Martínez B, Ordoñez AV, Garcia MS, Klünder MK, Parra-Ortega I, Acosta ED, et al. Thymidine Kinase: A Biomarker for Recently Diagnosed Acute Leukemia in Pediatric Patients According to the Cell Line Involved. Arch Med Res. 2015 Nov 30. DOI: 10.1016/j.arcmed.2015.11.005Gatt ME, Goldschmidt N, Kalichman I, Friedman M, Arronson AC, Barak V. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation. Anticancer Res. 2015 May; 35 (5): 3019–3026.Gatt ME, Goldschmidt N, Kalichman I, Friedman M, Arronson AC, Barak V. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation. Anticancer Res. 2015 May; 35 (5): 3019–3026.Procházka V, Faber E, Raida L, Langová K, Indrák K, Papajík T. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma. 2012 Jul; 53 (7): 1306–1310. DOI: 10.3109/10428194.2011.654339Procházka V, Faber E, Raida L, Langová K, Indrák K, Papajík T. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma. 2012 Jul; 53 (7): 1306–1310. DOI: 10.3109/10428194.2011.654339Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, Hamburger T, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010; 7 (2): 65–72. DOI: 10.3233/CBM-2010–0148Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, Hamburger T, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010; 7 (2): 65–72. DOI: 10.3233/CBM-2010–0148Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med. 2013 Feb; 51 (2): 439–447. DOI: 10.1515/cclm-2012–0162Nisman B, Allweis T, Kadouri L, Mali B, Hamburger T, Baras M, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med. 2013 Feb; 51 (2): 439–447. DOI: 10.1515/cclm-2012–0162Bolayirli M, Papila C, Korkmaz GG, Papila B, Aydoğan F, Karataş A, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal. 2013 May; 27 (3): 220–226. DOI: 10.1002/jcla.21587Bolayirli M, Papila C, Korkmaz GG, Papila B, Aydoğan F, Karataş A, et al. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal. 2013 May; 27 (3): 220–226. DOI: 10.1002/jcla.21587Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, et al. Serum thymidine kinase activity compared with CA 15–3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat. 2013 Jun; 139 (3): 751–758. DOI: 10.1007/s10549–013–2579-xBjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, et al. Serum thymidine kinase activity compared with CA 15–3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat. 2013 Jun; 139 (3): 751–758. DOI: 10.1007/s10549–013–2579-xChen F, Tang L, Xia T, He E, Hu G, Li Y, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol Clin Oncol. 2013 Sep; 1 (5): 894–902. DOI: 10.1515/cclm-2012–0162Chen F, Tang L, Xia T, He E, Hu G, Li Y, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol Clin Oncol. 2013 Sep; 1 (5): 894–902. DOI: 10.1515/cclm-2012–0162Huang ZH, Tian XS, Li R, Wang XM, Wen W, Guan H, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med. 2012 Feb; 3 (2): 331–335. DOI: 10.3892/etm.2011.395Huang ZH, Tian XS, Li R, Wang XM, Wen W, Guan H, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med. 2012 Feb; 3 (2): 331–335. DOI: 10.3892/etm.2011.395Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, et al. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22 (11): 2110–2115. DOI: 10.1158/1055–9965.EPI-13–0193Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, et al. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22 (11): 2110–2115. DOI: 10.1158/1055–9965.EPI-13–0193Alegre MM, Weyant MJ, Bennett DT, Yu JA, Ramsden MK, Elnaggar A, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res. 2014 May; 34 (5): 2145–2151. Available at: http://ar.iiarjournals.org/content/34/5/2145.longAlegre MM, Weyant MJ, Bennett DT, Yu JA, Ramsden MK, Elnaggar A, et al. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer. Anticancer Res. 2014 May; 34 (5): 2145–2151. Available at: http://ar.iiarjournals.org/content/34/5/2145.longLi HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005 Jan; 13 (1): 145–149. DOI: 10.3892/or.13.1.145Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep. 2005 Jan; 13 (1): 145–149. DOI: 10.3892/or.13.1.145Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010 Jul; 19 (4): 313–318. DOI: 10.1097/CEJ.0b013e32833ad320Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010 Jul; 19 (4): 313–318. DOI: 10.1097/CEJ.0b013e32833ad320Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers. 2013 Feb; 18 (1): 88–94. DOI: 10.3109/1354750X.2012.738250Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, et al. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers. 2013 Feb; 18 (1): 88–94. DOI: 10.3109/1354750X.2012.738250Nisman B, Nechushtan H, Biran H, Gantz-Sorotsky H, Peled N, Gronowitz S, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014 Oct; 9 (10): 1568–1572. DOI: 10.1097/JTO.0000000000000276.Nisman B, Nechushtan H, Biran H, Gantz-Sorotsky H, Peled N, Gronowitz S, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014 Oct; 9 (10): 1568–1572. DOI: 10.1097/JTO.0000000000000276.Topolcan O, Holubec L Jr, Finek J, Stieber P, Holdenrieder S, Lamerz R, et al. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res. 2005 May-Jun; 25 (3A): 1831–1833. Available at: http://ar.iiarjournals.org/content/25/3A/1831.longTopolcan O, Holubec L Jr, Finek J, Stieber P, Holdenrieder S, Lamerz R, et al. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res. 2005 May-Jun; 25 (3A): 1831–1833. Available at: http://ar.iiarjournals.org/content/25/3A/1831.longJi Y, Wu XB, Chen JY, Hu B, Zhu QK, Zhu XF, et al. Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma. Int J Clin Exp Med. 2015 Aug 15; 8 (8): 12850–7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612885/Ji Y, Wu XB, Chen JY, Hu B, Zhu QK, Zhu XF, et al. Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma. Int J Clin Exp Med. 2015 Aug 15; 8 (8): 12850–7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612885/Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med. 2011 Nov; 2 (6): 1177–1181. DOI: 10.3892/etm.2011.338Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med. 2011 Nov; 2 (6): 1177–1181. DOI: 10.3892/etm.2011.338Zhang SY, Lin BD, Li BR. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. FEBS Open Bio. 2015 Mar 26; 5: 240–244. DOI: 10.1016/j.fob.2015.03.010Zhang SY, Lin BD, Li BR. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. FEBS Open Bio. 2015 Mar 26; 5: 240–244. DOI: 10.1016/j.fob.2015.03.010Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev. 2009 Jun; 18 (3): 220–224. DOI: 10.1097/CEJ.0b013e328329d817Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev. 2009 Jun; 18 (3): 220–224. DOI: 10.1097/CEJ.0b013e328329d817Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010 Aug; 76 (2): 513.e1–6. DOI: 10.1016/j.urology.2010.04.034Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010 Aug; 76 (2): 513.e1–6. DOI: 10.1016/j.urology.2010.04.034Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep. 2006 Feb; 15 (2): 455–461. DOI: 10.3892/or.15.2.455Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep. 2006 Feb; 15 (2): 455–461. DOI: 10.3892/or.15.2.455Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol. 2013 Apr; 34 (2): 643–648. DOI: 10.1007/s13277–012–0591–0Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma. Tumour Biol. 2013 Apr; 34 (2): 643–648. DOI: 10.1007/s13277–012–0591–0Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010 Aug; 15 (4): 359–368. DOI: 10.1007/s10147–010–0067–4Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010 Aug; 15 (4): 359–368. DOI: 10.1007/s10147–010–0067–4Xu XH, Zhang YM, Shu XH, Shan LH, Wang ZW, Zhou YL, et al. Skog Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 2008 Sep-Oct; 1 (5): 705–711. DOI: 10.3892/mmr_00000017Xu XH, Zhang YM, Shu XH, Shan LH, Wang ZW, Zhou YL, et al. Skog Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 2008 Sep-Oct; 1 (5): 705–711. DOI: 10.3892/mmr_00000017Jagarlamudi KK, Hansson LO, Eriksson S. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. BMC Cancer. 2015 Feb 18; 15: 66. DOI: 10.1186/s12885–015–1073–8Jagarlamudi KK, Hansson LO, Eriksson S. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. BMC Cancer. 2015 Feb 18; 15: 66. DOI: 10.1186/s12885–015–1073–8He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005 Oct; 14 (4): 1013–1019. DOI: 10.3892/or.14.4.1013He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 2005 Oct; 14 (4): 1013–1019. DOI: 10.3892/or.14.4.1013Chen Z, Zhou H, Li S, He E, Hu J, Zhou J, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res. 2008 Nov-Dec; 28 (6B): 3897–3907. Available at: http://ar.iiarjournals.org/content/28/6B/3897.longChen Z, Zhou H, Li S, He E, Hu J, Zhou J, et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res. 2008 Nov-Dec; 28 (6B): 3897–3907. Available at: http://ar.iiarjournals.org/content/28/6B/3897.longHuang S, Lin J, Guo N, Zhang M, Yun X, Liu S, et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev. 2011; 12 (2): 497–505.Huang S, Lin J, Guo N, Zhang M, Yun X, Liu S, et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev. 2011; 12 (2): 497–505.Cao X, Wang Y, Yang P, Zhou H, Liu C, Chen Z. Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Oct; 39 (10): 1029–34. DOI: 10.11817/j.issn.1672–7347.2014.10.007Cao X, Wang Y, Yang P, Zhou H, Liu C, Chen Z. Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Oct; 39 (10): 1029–34. DOI: 10.11817/j.issn.1672–7347.2014.10.007Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours — a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel). 2011; 11 (12): 11064–11080. DOI: 10.3390/s111211064Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours — a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel). 2011; 11 (12): 11064–11080. DOI: 10.3390/s111211064

The authors declare that there are no conflicts of interest present.